| Literature DB >> 24672710 |
Gian Marco Tosi1, Davide Marigliani2, Tommaso Bacci2, Napoleone Romeo2, Angelo Balestrazzi2, Gianluca Martone2, Tomaso Caporossi3.
Abstract
Purpose. To evaluate the effectiveness and safety of perfluorohexyloctane (F6H8) for intraoperative flattening of the retina and of F6H8/silicone oil (SO) 1000 cSt as a postoperative tamponade for inferior retinal detachment with inferior proliferative vitreoretinopathy. Methods. This is a retrospective review of 22 patients who underwent pars plana vitrectomy using F6H8 as an intraoperative tool to flatten the retina. At the end of the surgery a direct partial exchange between F6H8 and SO 1000 cSt was performed, tamponing the eye with different ratios of F6H8/SO (70/30, 60/40, 50/50, 40/30, and 30/70). Anatomical and functional results and complications were evaluated over the follow-up period (mean 22.63 months). Results. F6H8 was efficacious for intraoperative flattening of the retina. Twenty-one of the 22 patients achieved a complete retinal reattachment. Postoperative visual acuity (VA) ranged from light perception to 20/70, with 72% of patients obtaining VA better than 20/400. No emulsification/inflammation was observed whatever the ratio of F6H8/SO used. With higher ratios of F6H8/SO (70/30 and 60/40) cloudiness of the tamponade was observed. A transparent mixture was present with all the other ratios. Conclusions. The surgical technique adopted is very simple and safe. The optimal F6H8/SO ratio seems to be between 50/50 and 30/70.Entities:
Year: 2014 PMID: 24672710 PMCID: PMC3941958 DOI: 10.1155/2014/956831
Source DB: PubMed Journal: J Ophthalmol ISSN: 2090-004X Impact factor: 1.909
Clinical data of patients with inferior retinal detachment and inferior PVR.
| Patient | age/sex | Visual acuity at entrance examination | Diagnosis | Associated ocular abnormalities | Previous retinal surgery | Lens status | Surgery with fluoron tamponade | F6H8/SO ratio | Problems with fluoron | Procedure after fluoron use | Fluoron removal (time between use and removal) | Complications | Actual status | Followup |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 80/F | CF | RD, PVR | Retinoschisis | None | P | SB-PE-IOLI-Vx-F | 70/30 | TCT, PS | FR | 4 | None | CF, A | 40 |
| 2 | 34/M | CF | RD, PVR | HM | SB | PP | Vx-F | 70/30 | TCT | FR | 3 | Inflammatory reaction 1 y after FR | LP, D | 36 |
| 3 | 67/M | CF | RD, PVR | CED | Vx-SO; Vx-SO | AP | SB-Vx-F; Vx-R-F | 70/30; | TCT, PVR | SF-FR | 2, 3 | None | 20/100, A | 32 |
| 4 | 68/M | CF | RD, PVR | GL | PE-IOLI-Vx-SO; SB-Vx-SO | PP | Vx-R-F | 60/40 | TCT | FR | 3 | None | 20/100, A | 48 |
| 5 | 67/F | LP | RD, PVR | GL, CED | SB-Vx-SO | PP | Vx-F | 60/40 | TCT | FR | 3 | None | CF, A | 36 |
| 6 | 80/M | CF | RD, PVR | HM | SB-Vx-G | PP | Vx-F | 60/40 | TCT, H | FR-SO | 3 | H | 20/200, A, SO not removed | 28 |
| 7 | 74/F | MM | RD, PVR | GL | SB | PP | Vx-R-F | 60/40 | TCT | FR-MP-G | 3 | None | 20/200, A | 28 |
| 8 | 78/F | LP | RD, PVR | H | SB-Vx-SO | PP | Vx-F | 60/40 | TCT, PS, H | FR-SO | 4 | H | 20/200, H, A, SO not removed | 36 |
| 9 | 54/M | MM | RD, PVR | GL, HM | T; PE-IOLI-Vx-G | PP | Vx-F; Vx-F | 60/40; 50/50 | PS, H, TCT, PVR | FR-G | 3, 4 | H (4 month duration) | 20/200, A | 18 |
| 10 | 58/M | CF | RD, PVR | None | SB-Vx-SO | PP | Vx-F | 50/50 | H | FR | 3 | None | 20/100, H, A | 16 |
| 11 | 80/F | CF | RD, PVR | HM | None | PP | SB-Vx-MP-F | 50/50 | F in anterior chamber | FR | 3 | None | 20/200, A | 12 |
| 12 | 58/M | CF | RD, PVR | None | SB-Vx-SO | PP | Vx-F | 40/60 | None | FR | 3 | None | 20/200, A | 16 |
| 13 | 70/M | LP | RD, PVR | None | None | PP | SB-Vx-F | 40/60 | Inferior retinal hemorrhages | FR | 5 | None | 20/100, A | 12 |
| 14 | 78/F | CF | RD, PVR | None | SB-Vx-SO | PP | Vx-F | 30/70 | Superior PVR | FR-R-SO; SOR | 3 | None | 20/100, A | 12 |
| 15 | 81/M | 20/400 | RD, PVR | None | None | PP | SB-Vx-F | 30/70 | None | FR | 3 | None | 20/70, A | 12 |
| 16 | 79/F | LP | RD, PVR | None | None | PP | SB-Vx-F | 30/70 | Macular PVR, PS | None | — | None | CF, A, F not removed | 14 |
| 17 | 84/M | CF | RD, PVR | FB | None | P | PE-SB-Vx-R-F-FBR | 30/70 | Superior PVR, H | FR, Vx-MP-SO; | 1 | H | CF, H, A, SO not removed | 12 |
| 18 | 76/F | 20/400 | RD, PVR | None | None | PP | SB-Vx-F | 30/70 | None | FR | 5 | CME | 20/100, A | 12 |
| 19 | 55/F | MM | RD, PVR | None | None | PP | SB-Vx-F | 30/70 | CME | FR | 3 | CME (3-month duration) | 20/80, A | 12 |
| 20 | 80/M | CF | RD, PVR | None | None | PP | SB-Vx-F | 30/70 | None | FR | 3 | None | 20/100, A | 42 |
| 21 | 74/M | CF | RD, PVR | None | None | P | SB-PE-Vx-F | 30/70 | PS | FR | 3 | None | 20/100, A | 12 |
| 22 | 56/F | CF | RD, PVR | HM | PE-IOLI-SB-Vx-G; Vx-SO | PP | Vx-MP-F | 30/70 | Superior PVR | FR-Vx-MP-SO; SOR | 3 | None | 20/400, A | 12 |
A: attached; AP: aphakia; CED: corneal endothelial dystrophy; CF: count fingers; CME: cystoid macular edema; D: detached; F: F6H8; FB: foreign body; FBR: foreign body removal; FR: F6H8 removal; G: gas; GL: glaucoma; H: hypotony; M: high myopia; IOLI: intraocular lens implantation; LP: light perception; HM: hand motions; MP: membrane peeling; P: phakia; PE: phacoemulsification; PP: pseudophakia; PS: posterior synechiae; PVR: proliferative vitreoretinopathy; R: retinotomy; RD: retinal detachment; SB: scleral buckle; SF: scleral fixation; SO: silicone oil; SOR: silicone oil removal; T: trabeculectomy; TCT: temporary cloudiness of the tamponade; Vx: vitrectomy.